Astrazeneca Taiwan company information, Employees & Contact Information

Pharmaceuticals in the environment AstraZeneca

AstraZeneca unveils expanded manufacturing facility in Texas Business Wire

FLUMIST® (Influenza, Vaccine Live, Intranasal), the nation’s only nasal spray flu vaccine, now available for home delivery AstraZeneca US

AstraZeneca plans to increase investment and scope of its Virginia manufacturing facility to $4.5 billion, creating 3,600 new jobs Business Wire

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab granted Priority Review in the US as 1st-line treatment for patients with HER2-positive metastatic breast cancer AstraZeneca US

AstraZeneca and Global Transparency AstraZeneca

Thermo Fisher Scientific Announces R&D Partnership with AstraZeneca BioVentureHub Business Wire

SAPHNELO self-administration TULIP-SC Phase III trial meets primary endpoint in patients with systemic lupus erythematosus based on an interim analysis AstraZeneca US

Community investment AstraZeneca

AstraZeneca furthers ambition to redefine cancer care with first data from four major pivotal trials at ESMO Business Wire

Baxdrostat demonstrated statistically significant and clinically meaningful reduction in systolic blood pressure in patients with hard-to-control hypertension in the BaxHTN Phase III trial AstraZeneca US

Sustainability partnerships and alliances AstraZeneca

AstraZeneca plans to invest $50 billion in America for medicines manufacturing and R&D Business Wire

Rooted in Legacy, Leading into the Future AstraZeneca US

Our approach to Water stewardship AstraZeneca

Update on the RESOLUTE Phase III trial for FASENRA in chronic obstructive pulmonary disease AstraZeneca US

Healthy forests for healthy people – expanding our investment in climate action and nature AstraZeneca

Collaborating to redefine cancer care in Africa AstraZeneca

Data Visualisation – Turning Science into Stories AstraZeneca

AstraZeneca’s record seventh year of plenary data at ASCO furthers ambition to redefine breast cancer care and transform outcomes in gastric cancer AstraZeneca US

IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial AstraZeneca US

AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial AstraZeneca US

AstraZeneca results: H1 and Q2 2025 Business Wire

AstraZeneca Announces Plans to Harmonize Global Listing Structure for Stock Exchanges Alongside Positive Enhertu Updates Pharmaceutical Executive

AIRSUPRA ® (albuterol/budesonide) US prescribing information updated to reflect the statistically significant severe exacerbation risk reduction in patients with mild asthma compared with albuterol AstraZeneca US

AstraZeneca launches direct-to-consumer platform to expand access to medications for US patients, including those living with chronic conditions Business Wire

Eneboparatide met primary endpoint of normalizing serum calcium in adults with hypoparathyroidism at 24 weeks in CALYPSO Phase III trial AstraZeneca US

Statistically significant and clinically meaningful BATURA Phase III trial results provide new evidence for AIRSUPRA as standard of care for as-needed rescue treatment in asthma AstraZeneca US

AstraZeneca's Q1 2025 Financial Results Business Wire

DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer AstraZeneca US

Annual report 2023 AstraZeneca

AstraZeneca and Erin Andrews team up to inspire fans to Get Body Checked Against Cancer Business Wire

Rare Disease Therapeutics AstraZeneca

Daiichi Sankyo, AstraZeneca Withdraw EU MAA for Dato-DXd in Advanced Nonsquamous NSCLC OncLive

TRUQAP® (capivasertib) combination in PTEN-deficient metastatic hormone-sensitive prostate cancer demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Phase III trial AstraZeneca US

AstraZeneca means 'a road to death' in Latin? Snopes

Gaithersburg AstraZeneca

Introducing AstraZeneca R&D AstraZeneca

Coronavirus (COVID-19) information & research hub AstraZeneca

Precision medicine AstraZeneca

Medicines - Our focus areas AstraZeneca

Full Year and Q4 2023 results AstraZeneca

Data Science & Artificial Intelligence: Unlocking new science insights AstraZeneca

African Cluster AstraZeneca

Our approach to clinical innovation AstraZeneca

Susan Galbraith, EVP Oncology R&D AstraZeneca

AstraZeneca’s Full Year and Q4 2024 results Business Wire

A.Catalyst Network AstraZeneca

AstraZeneca Coupa Supplier Hub AstraZeneca

Respiratory and Immunology - Our therapy areas AstraZeneca

H1 and Q2 2024 results AstraZeneca

Next generation therapeutics AstraZeneca

Oncology partnerships driving innovation AstraZeneca

Harnessing the power of cell therapy AstraZeneca

Israel - AstraZeneca AstraZeneca

Oncology – AstraZeneca - Redefining Cancer Care AstraZeneca

Indonesia AstraZeneca

At the forefront of lung cancer treatment AstraZeneca

A big future for small molecules: targeting the undruggable AstraZeneca

About Our Company AstraZeneca

Science, innovation and technology AstraZeneca

Haematology - How we are transforming blood cancer care AstraZeneca

Partnering AstraZeneca

AstraZeneca invests $3.5 billion in R&D and manufacturing in the United States Business Wire

Egypt AstraZeneca

AstraZeneca awards $3.5M for projects to improve access to healthcare for patients across the US Business Wire

Breast Cancer AstraZeneca

Transforming long-term outcomes in prostate cancer AstraZeneca

Sunil Verma AstraZeneca

Our leadership AstraZeneca

Our Oncology Clinical Strategy is designed to transform survival AstraZeneca

Externally Sponsored Scientific Research AstraZeneca

Liver Cancer AstraZeneca

Delivering medicines to people who need them most. AstraZeneca

Sustainability at AstraZeneca AstraZeneca

Sustainability reports and resources AstraZeneca

Maurizio Scaltriti AstraZeneca

Cristina Durán AstraZeneca

TEZSPIRE met both co-primary endpoints in the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps AstraZeneca US

Gulf AstraZeneca

Calquence approved in the US for adult patients with chronic lymphocytic leukaemia AstraZeneca

What science can do AstraZeneca

Ireland AstraZeneca

AstraZeneca announces innovative partnership with Vanguard Renewables to decarbonize its United States sites AstraZeneca US

What science can do AstraZeneca US

Saudi Arabia AstraZeneca

The Philippines AstraZeneca

Regina Fritsche-Danielson AstraZeneca

Immuno-oncology: harnessing the power of the immune system AstraZeneca

IMFINZI® (durvalumab) perioperative regimen reduced the risk of recurrence by 32% and the risk of death by 25% vs. neoadjuvant chemotherapy alone in muscle-invasive bladder cancer in the NIAGARA Phase III trial AstraZeneca US

Affordability AstraZeneca US

Cell origins lead to targeted and regenerative therapies AstraZeneca

Contact Us AstraZeneca US

ADR programme AstraZeneca

Imfinzi approved in China for the treatment of unresectable, Stage III non-small cell lung cancer based on the Phase III PACIFIC trial AstraZeneca

Ruth March AstraZeneca

Datopotamab deruxtecan significantly extended progression-free survival vs. chemotherapy in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial AstraZeneca US

US Food and Drug Administration accepts for review AstraZeneca’s Supplemental Biologics License Application for self-administration of FLUMIST® QUADRIVALENT (Influenza Vaccine Live, Intranasal) AstraZeneca US

AstraZeneca Singapore AstraZeneca

Careers AstraZeneca US